重组人干扰素α-1b联合利巴韦林治疗流行性腮腺炎的临床效果  

Clinical Efficacy of Recombinant Human Interferonα-1b Combined with Ribavirin in the Treatment of Mumps

作　　者：刘艳会 Liu Yanhui(Second Inpatient Ward,Department of Infectious Diseases of Xiangyang Municipal Hospital of Infectious Diseases,Xiangyang 441000,Hubei Province,China)

机构地区：[1]襄阳市传染病医院传染科二病区,湖北襄阳441000

出　　处：《中外医药研究》2025年第7期33-35,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察重组人干扰素α-1b联合利巴韦林治疗流行性腮腺炎的临床效果。方法:选取2022年9月—2023年9月襄阳市传染病医院传染科收治的流行性腮腺炎患儿64例,随机分为对照组和观察组,各32例。对照组接受利巴韦林治疗,观察组接受重组人干扰素α-1b联合利巴韦林治疗。比较两组症状改善情况、炎性反应指标、免疫功能指标。结果:观察组退热时间、腮腺肿胀消失时间、食欲好转时间、疼痛消失时间短于对照组(P<0.05);治疗后,两组血清可溶性白细胞介素-2受体、白细胞介素-6、肿瘤坏死因子-α水平降低,观察组低于对照组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平升高,CD8^(+)水平降低,观察组优于对照组(P<0.05)。结论:重组人干扰素α-1b联合利巴韦林治疗流行性腮腺炎的临床效果较好,可以改善患儿症状,减轻炎性反应,提高免疫功能。Objective:To observe the clinical efficacy of recombinant human interferon α-1b combined with ribavirin in the treatment of mumps.Methods:A total of 64 children with mumps admitted to the Department of Infectious Diseases of Xiangyang Municipal Hospital of Infectious Diseases from September 2022 to September 2023 were selected and randomly divided into a control group and an observation group,with 32 cases in each group.The control group received ribavirin treatment,while the observation group received recombinant human interferonα-1b combined with ribavirin treatment.The improvement of symptoms,inflammatory response indicators,and immune function indicators were compared between the two groups.Results:The duration of fever,parotid gland swelling disappearance,appetite improvement,and pain disappearance in the observation group were shorter than those in the control group(P<0.05).After treatment,the levels of serum soluble interleukin-2 receptor,interleukin-6,and tumor necrosis factor-αin both groups decreased,with the observation group showing lower levels than the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)increased,while the level of CD8^(+)decreased in both groups,with the observation group showing better results than the control group(P<0.05).Conclusion:Recombinant human interferonα-1b combined with ribavirin demonstrates favorable clinical efficacy in the treatment of mumps,effectively improving symptoms,reducing inflammatory response,and enhancing immune function.

关 键 词：重组人干扰素Α-1B 利巴韦林 流行性腮腺炎 

分 类 号：R512.1[医药卫生—内科学]